You searched for "anti-VEGF"

13 results found

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Systemic pharmacology of intravitreal anti-VEGF

This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...

Type 3 CNV and anti-VEGF

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Combined anti-VEGF and PDT for wet AMD

The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...

Effect of anti-VEGF treatment on PED morphology

This retrospective study of 30 eyes assessed the effect of anti-VEGF on morphology of pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD). Thirty eyes of 28 patients with PED were compared to 30 eyes of 30 patients with...

Endophthalmitis after intravitreal anti-VEGF injection

The authors report the results of a retrospective multicentre study conducted at 17 retina referral centres to investigate the microbial spectrum of endophthalmitis after anti-VEGF injections. A total of 83 cases of culture-positive endophthalmitis (58.4%) were included. The most frequent...

21st Century retinal laser treatment in the anti-VEGF era

In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...

Licence to save: a UK survey of anti-VEGF use for the eye

This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Can intravitreal anti-VEGF injections affect corneal nerves?

This was a retrospective case-control study looking at the effect of anti-VEGF injections on corneal nerves (CN). Fifty-seven patients with a history of at least three anti-VEGF injections in one or both eyes and available confocal microscopic imaging were included...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion

Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...

Rituximab as an immunosuppression treatment for thyroid eye disease

Thyroid eye disease is traditionally treated with high dose glucocorticosteroids and surgical orbital decompression, where responses are often inadequate. This medical treatment is centred around symptom control and reduction of thyroid hormone synthesis, not immunosuppression. Rituximab is an anti-CD20 monoclonal...
  • 1 (current)
  • 2